Rauch Gaiane M, Adrada Beatriz Elena, Kuerer Henry Mark, van la Parra Raquel F D, Leung Jessica W T, Yang Wei Tse
1 Department of Diagnostic Radiology, Unit 1473, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009.
2 Department of Diagnostic Radiology, Unit 1350, The University of Texas MD Anderson Cancer Center, Houston, TX.
AJR Am J Roentgenol. 2017 Feb;208(2):290-299. doi: 10.2214/AJR.16.17223. Epub 2016 Nov 3.
Neoadjuvant chemotherapy is becoming the standard of care for patients with locally advanced breast cancer. Conventional imaging modalities used for the assessment of tumor response to neoadjuvant chemotherapy rely on changes in size or morphologic characteristics and, therefore, are inherently limited.
Functional imaging technologies evaluate vascular, metabolic, biochemical, and molecular changes in cancer cells and have a unique ability to detect specific biologic tumor markers, assess therapeutic targets, predict early response to neoadjuvant chemotherapy, and guide individualized cancer therapy.
新辅助化疗正成为局部晚期乳腺癌患者的标准治疗方案。用于评估肿瘤对新辅助化疗反应的传统成像方式依赖于大小或形态特征的变化，因此存在固有局限性。
功能成像技术可评估癌细胞的血管、代谢、生化和分子变化，具有独特能力来检测特定的生物肿瘤标志物、评估治疗靶点、预测对新辅助化疗的早期反应并指导个体化癌症治疗。
